EUVIMEDEUVIMED entdecken
Multizentrische Studie

Accurate evaluation of factor VIII activity of efanesoctocog alfa in the presence of emicizumab

Christophe Nougier, Steven W Pipe, Ingrid Pabinger, Claire Pouplard, Roger E G Schutgens, Cedric Hermans, Guy Young, Edison Sexton, Peter Quehenberger, Eve-Anne Guery, Albert Huisman, Marie-Astrid Van Dievoet und 2 weitere

Journal of Thrombosis and Haemostasis · 2025-05 · 23 (5) · 1516-1521

DOI: 10.1016/j.jtha.2024.12.034 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025-05. Verfasst von Christophe Nougier und 13 weiteren Autor:innen. Beteiligte Einrichtung: French Reference Center for Hemophilia, Hospices Civils de Lyon, Hemostasis&Thrombosis, UR4609 Universite Claude Bernard Lyon 1, Lyon, France. Hauptthemen laut MEDLINE: Factor VIII, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Hemophilia A. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Efanesoctocog is a B-domain-deleted, Fc-fusion factor (F)VIII linked to the D'D3 domain of von Willebrand factor and 2 XTEN polypeptides, designed for an ultra-extended half-life for prophylaxis in hemophilia A, but also aiding in managing acute bleeding or surgery in patients on long-term emicizumab. However, no current laboratory method accurately measures FVIII levels in the presence of emicizumab. OBJECTIVES: To test whether the bovine chromogenic FVIII assay, specifically calibrated for efanesoctocog, could provide an accurate assessment of efanesoctocog activity. METHODS: Seven centers across 5 countries received 12 plasma samples to measure in triplicate using 2 calibration methods across 3 independent days. Samples (n = 6) contained either only efanesoctocog (FVIII activity [FVIII:C]= 5 to 150 IU/dL), or efanesoctocog (FVIII:C = 5 to 150 IU/dL) in combination with emicizumab (50 μg/mL; n = 5). One sample contained efanesoctocog (FVIII:C = 50 IU/dL) and a high dose of emicizumab (80 μg/mL); another sample contained efanesoctocog (FVIII:C = 50 IU/dL) with a low dose of emicizumab (20 μg/mL). Each center used its own analyzers, along with their usual reagents. RESULTS: Chromogenic assay (CSA) calibrated with standard calibrators highly overestimates FVIII:C. However, specific calibration with efanesoctocog enabled accurate measurement of FVIII:C, with low inter- and intra-laboratory variability, and no interference from emicizumab. All CSA reagents used in the study demonstrated low variability across different laboratories (interlaboratory coefficient of variation ranges between 9% and 20%). CONCLUSION: Specific calibration of the FVIII CSA using efanesoctocog and bovine reagents allows for accurate measurement of FVIII:C in patients receiving efanesoctocog, even in the presence of emicizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor VIIIAntibodies, BispecificAntibodies, Monoclonal, HumanizedHemophilia ABlood CoagulationDrug MonitoringHumansReproducibility of ResultsCalibrationAnimalsBlood Coagulation TestsCattleChromogenic CompoundsPredictive Value of Tests

Stichwörter der Autor:innen

chromogenic assayefanesoctocog alfaemicizumabfactor VIIIspecific calibration

Substanzen

emicizumabFactor VIIIAntibodies, BispecificAntibodies, Monoclonal, HumanizedF8 protein, humanChromogenic Compounds

Autor:innen und Institutionen

  • French Reference Center for Hemophilia, Hospices Civils de Lyon, Hemostasis&Thrombosis, UR4609 Universite Claude Bernard Lyon 1, Lyon, France.
  • Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
  • Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Department of Haemostasis, University Hospital of Tours, Tours, France.
  • Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Division of Haematology, Saint-Luc University Hospital, Catholic University of Louvain, Brussels, Belgium.

Zitieren

APA

Nougier, C., Pipe, S. W., Pabinger, I., Pouplard, C., Schutgens, R. E. G., Hermans, C., Young, G., Sexton, E., Quehenberger, P., Guery, E. A., Huisman, A., Van Dievoet, M. A., Marquez, E., & Dargaud, Y. (2025). Accurate evaluation of factor VIII activity of efanesoctocog alfa in the presence of emicizumab. Journal of Thrombosis and Haemostasis, 23(5), 1516-1521. https://doi.org/10.1016/j.jtha.2024.12.034

Vancouver

Nougier C, Pipe SW, Pabinger I, Pouplard C, Schutgens REG, Hermans C, et al. Accurate evaluation of factor VIII activity of efanesoctocog alfa in the presence of emicizumab. Journal of Thrombosis and Haemostasis. 2025;23(5):1516-1521. doi:10.1016/j.jtha.2024.12.034

BibTeX
@article{Nougier2025,
  author = {Nougier, Christophe and Pipe, Steven W and Pabinger, Ingrid and Pouplard, Claire and Schutgens, Roger E G and Hermans, Cedric and Young, Guy and Sexton, Edison and Quehenberger, Peter and Guery, Eve-Anne and Huisman, Albert and Van Dievoet, Marie-Astrid and Marquez, Elizabeth and Dargaud, Yesim},
  title = {Accurate evaluation of factor VIII activity of efanesoctocog alfa in the presence of emicizumab},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  volume = {23},
  number = {5},
  pages = {1516--1521},
  doi = {10.1016/j.jtha.2024.12.034}
}
Kostenlos starten →